D.YU. VENIDIKTOVA

Smolensk State Medical University, Smolensk, Russia

 Contact details:

Venidiktova D.Yu. — post-graduate student of the Domain-specific Scientific-research Laboratory «Diagnostic research and minimally invasive technologies»

Address: 31 Normandia-Neman St., Smolensk, Russian Federation, 214025, tel.: +7-910-785-03-71, e-mail: 92darv@gmail.com

The purpose — to determine the effect of patient’s compliance level on the appointment of personalized non-drug treatment of non-alcoholic fatty liver disease (NAFLD).

Material and methods. 208 patients with excess body mass were examined, 177 patients with excess fat mass (according to the bioimpedance analyses) were included into the study. The patients (n = 93) were divided into groups according to their compliance level: Group 1 (n = 31, 33.3%) — low level; Group 2 (n = 38, 40.9%) — average level; Group 3 (n = 24, 25.8%) — high level of compliance. The period of observation was 3 months. The treatment program was selected depending on the compliance and physical activity levels. The control group (n = 84) included patients without personalized treatment. The unified diagnostic algorithm applied to all patients included biochemical blood test parameters, quantitative ultrasound steatometry within the combined elastography, and dual-energy X-ray absorptiometry in the «Whole body» mode.

Results. Groups of patients were formed according to the NAFLD stage: hepatic steatosis (n = 23, 24.7%), steatohepatitis with liver fibrosis F0-F1 (n = 41, 44.1%), steatohepatitis with liver fibrosis F2-F3 (n = 27, 29%), liver cirrhosis F4 (n = 2, 2.2%). The connection was revealed between the NAFLD stage decrease in the direction “fibrosis → steatohepatitis → steatosis” (with a fat mass index decrease) and the compliance level, which served as the basis for the non-drug treatment tactics.

Conclusion. A preliminary assessment of the patient’s compliance for the NAFLD non-drug treatment is effective for the progressing along the disease stages of reduction of clinical and morphological manifestations. Quantitative ultrasound steatometry with dual-energy X-ray absorptiometry in the «Whole body» mode can be used in patients refusing liver biopsy.

Key words: compliance, ultrasound steatometry, non-alcoholic fatty liver disease.

REFERENCES

1. Kontsevaya A. et al. Overweight and obesity in the Russian population: prevalence in adults and association with socioeconomic parameters and cardiovascular risk factors. Obesity facts, 2019, vol. 12 (1), pp. 103–114.
2. Ge X. et al. Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study. BMJ open, 2020, vol. 10 (8), p. e036663.
3. Takahashi Y., Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World journal of gastroenterology: WJG, 2014, vol. 20 (42), p. 15539.
4. Maev I.V. et al. Modern and promising approaches to the diagnosis of non-alcoholic fatty liver disease. Consiliummedicum, 2015, vol. 17, no. 8 (in Russ.).
5. Morozova T. G., Borsukov A.V., Mamoshin A.V. Complex elastography of the liver and pancreas. Meditsinskaya vizualizatsiya, 2015, no. 3, pp. 75–83 (in Russ.).
6. Romero-Gómez M., Zelber-Sagi S., Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of hepatology, 2017, vol. 67 (4), pp. 829–846.
7. El-Agroudy N.N. et al. Are lifestyle therapies effective for NAFLD treatment? Trends in Endocrinology & Metabolism, 2019, vol. 30 (10), pp. 701–709.
8. Venidiktova D.Yu., Borsukov A.V. Possibilities of dual-energy X-ray absorptiometry in the diagnostic algorithm in patients with non-alcoholic fatty liver disease. Luchevaya diagnostika i terapiya, 2017, no. 2, pp. 74–75 (in Russ.).
9. Gureeva I.L. Clinical and psychological characteristics of patients with metabolic syndrome. Tendentsii razvitiya nauki i obrazovaniya, 2019, no. 55–8, pp. 36–39 (in Russ.).
10. Borsukov A.V., Venidiktova D.Yu. Ultrasound diagnostics of liver steatosis: development of a new method for quantitative assessment of the pathological process. Meditsinskiy alfavit, 2017, vol. 2, no. 19, pp. 47–51 (in Russ.).
11. Zhirkov I.I. et al. Strategy for the diagnosis of non-alcoholic fatty liver disease. Vestnik Rossiyskoy voenno-meditsinskoy akademii, 2019, no. 3, pp. 195–200 (in Russ.).
12. Kadyrov R.V., Asriyan O.B., Koval’chuk S.A. Oprosnik «Uroven’ komplaentnosti» [Compliance level questionnaire], 2014.
13. Aronov D.M., Krasnitskiy V.B., Bubnova M.G. Oprosnik dvigatel’noy aktivnosti «ODA 23+» [Physical activity questionnaire «ODA 23+»], 2013.